{'fraction_non_alphanumeric': 0.03582089552238806, 'fraction_numerical': 0.0052238805970149255, 'mean_word_length': 5.841836734693878, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
VIRUS INACTIVATION IN CELLULAR COMPONENTS

Despite the increased safety of blood achieved by continued improvements in donor testing, concern remains about the safety of blood products. Currently, prevention of infectious disease associated with the transfusion of cellular components rests largely on pre-transfusion donor evaluation. Transfusion of cellular components has been implicated in transmission of viral, bacterial, and protozoan diseases (1). While it is commonly recognized that hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), and the retroviruses, such as human immunodeficiency virus (HIV) and the human lymphotrophic viruses (HTLV) can be transmitted by cellular components, other pathogens are emerging as potentially significant transfusion-associated infectious agents. For example, transmission of protozoan infections due to trypanosomes (2-4) and babesia have been reported (5). In addition to viral and protozoal infectious agents, bacterial contamination of platelet concentrates continues to be reported (6, 7); and may be an under reported transfusion complication (8) . More importantly, new infectious agents, for example hepatitis G virus (HGV), may enter the donor population before they can be definitively identified and tested for to maintain consistent safety of the blood supply.